BiotechTube

LY3295668

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neoplasms

Conditions

Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms, Head and Neck Neoplasms, Breast Neoplasms, Solid Tumor, Adult, Small Cell Lung Carcinoma

Trial Timeline

May 29, 2017 → Apr 20, 2020

NCT ID
NCT03092934

About LY3295668

LY3295668 is a phase 1/2 stage product being developed by Eli Lilly for Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT03092934. Target conditions include Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasms were approved

Approved (20) Terminated (2) Active (0)
✅LenvatinibEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Chlorhydrate de RopivacaineAstraZenecaApproved
✅Sitagliptin + placeboMerckApproved
✅Palonosetron and DexamethasoneMerckApproved

Hype Score Breakdown

Clinical
9
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03092934Phase 1/2Completed

Competing Products

20 competing products in Neoplasms

See all competitors
ProductCompanyStageHype Score
ADC-1013Alligator Bioscience ABPhase 1
19
AB0024Gilead SciencesPhase 1
29
TTI-237PfizerPhase 1
21
852APfizerPhase 1
29
PemetrexedEli LillyPhase 2
35
IMC-3C5Eli LillyPhase 1
29
Galunisertib + Gemcitabine + PlaceboEli LillyPhase 1/2
32
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
LY2784544Eli LillyPhase 1
29
enzastaurinEli LillyPhase 2
35
Abemaciclib + Darolutamide + LHRH agonist/antagonistEli LillyPhase 1
29
Gemcitabine + liposomal doxorubicinEli LillyPhase 3
40
120 mg LY2784544Eli LillyPhase 2
39
LY4337713Eli LillyPhase 1
36
pemetrexed + cisplatinEli LillyPhase 1/2
32
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
47
VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mgVincerx PharmaPhase 1
19
VIP236 (Q3W) + VIP236 (Q2W)Vincerx PharmaPhase 1
19
GEMZAR + ALIMTAEli LillyPhase 3
40